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Sung Ha Lee 
 
NEURONAL ADAPTATIONS IN THE NUCLEUS ACCUMBENS CORE UNDER 
ACUTE AND CHRONIC EXPOSURE TO CANNABINOIDS 
 
Cannabis, known as marijuana, is the most commonly used illicit drug in the 
United States, but we have limited knowledge about its effects on the brain, 
particularly the reward circuitry. Cannabinoids, the psychoactive ingredient of 
cannabis, activate cannabinoid receptors in the mesolimbic area, resulting in 
increased dopamine transmission in the nucleus accumbens (NAc). This effect is 
believed to enhance goal-directed behavioral responses, including the motivation 
to obtain natural and drug rewards, but NAc signaling under cannabinoid 
exposure remain largely unknown. To address this gap, this dissertation work 
examines two main signaling changes in the NAc core: neuronal activities and 
dopamine dynamics.  
Since cannabis derivatives are usually used for a prolonged time, ongoing 
changes in the NAc core were investigated in response to acute and repeated 
exposure of cannabinoids. Therefore, in Experiment 1, NAc neuronal signaling 
was obtained on initial and repeated exposure (seven daily injections) of a 
cannabinoid receptor agonist, CP55,940 (0.2 mg/kg or 0.4 mg/kg) in male 
Sprague–Dawley rats using an in vivo electrophysiology technique. The overall 
effect of CP55,940 on CB1/2 receptor activation acutely inhibited NAc neuron 
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activity and reduced correlated neuronal activity/burst firing, and these effects 
lasted for the seven days of injections. This result suggests that cannabinoids 
reduce neuronal signaling and disrupt functional communication in the NAc core 
for a prolonged period. However, cannabinoid increased the theta power of local 
field potentials after acute CP55,940 injection but repeated treatment failed to 
maintain this effect.  
In Experiment 2, the electrically evoked dopamine overflow was collected using 
fast scan cyclic voltammetry (FSCV). Using kinetic analysis, dopamine release 
and reuptake were assessed immediately following one or seven daily injections 
of CP55,940 (0.2 mg/kg, i.p.) or a vehicle. A single injection of CP55,940 
increased the stimulation-evoked dopamine concentration without altering 
dopamine reuptake. However, repeated CP55,940 exposure led to a similar level 
of dopamine concentration as the chronic vehicle treatment.  
The sustained neuronal signaling but altered dopamine dynamics in the NAc core 
after repeated cannabinoid exposure suggest separate mechanisms in the 
development of tolerance. As the present results indicate, altered signaling of the 
NAc core could provide evidence of changes in motivational states that, in turn, 
may play a role in changing reward-related behaviors. 
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 1 
Introduction 
 
In Western countries, marijuana, derived from the plant cannabis savita, is the 
most widely used illicit drug for recreational use (Cadoni, Pisanu, Solinas, & 
Acquas, 2001). Human marijuana users have generally reported that smoking 
marijuana produces relaxation, a sense of euphoria and a feeling of well-being 
(D'Souza et al., 2008). The well-known primary psychoactive component of 
cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist of cannabinoid 
receptor 1 (CB1). Both synthetic cannabinoid receptor agonists (e.g., WIN 55,212 
and CP55,940) and THC are known to excite CB1 receptors in the brain. Like 
humans, animals also appear to find cannabinoid agonists to be rewarding; 
animals prefer cannabinoids over saline in conditioned place preference (Braida, 
Pozzi, Parolaro, & Sala, 2001b), cannabinoids lower intracranial self stimulation 
(ISCC) (Gardner et al. 1988;Negus & Miller, 2014), and animals are able to self 
administer cannabinoids (Tanda & Goldberg, 2003). 
 
The rewarding effect of cannabinoids comes from activation of the brain reward 
circuitry. Addictive drugs including cannabis are characterized by increasing 
extracellular dopamine in the synapse of dopaminergic neurons projected from 
ventral tegmental area (VTA) (Di Chiara, 1997). The axons from dopaminergic 
neurons project primarily into the nucleus accumbens (NAc) and the medial 
prefrontal cortex (PFC) (Riegel & Lupica, 2004) and form the mesolimbic 
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pathway and mesocortical pathway, respectively. Phasic dopamine release in the 
reward circuit including meso- and corticolimbic regions encodes natural rewards 
including food, sex, and social interactions (Kelley & Berridge, 2002) as well as 
addiction to drugs of abuse (Nestler, 2005). 
 
 
Figure 1. Brain reward circuitry. A simplified diagram of the major 
dopaminergic (green), glutamatergic (red), and GABAergic (blue) connections 
among the ventral tegmental area (VTA), nucleus accumbens (NAc) and medial 
prefrontal cortex (mPFC).  
 
Endocannabinoid signals in the mesolimbic pathway  
Cannabinoids primarily act on the endocannabinoid system, which is comprised 
of cannabinoid receptors and endogenous cannabinoids. The two best-known 
endogenous ligands for cannabinoid receptors are anadamide (AEA) (Devane et 
al., 1992) and 2-arachidonoylglycerol (2-AG) (Sugiura, Kodaka, Kondo, & 
Tonegawa, 1996). Both are derived from arachidonic acid in the cell membrane 
and released “upon demand” (stimulation) without being stored in vesicles. The 
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first cannabinoid receptor, called CB1, was sequenced and cloned (Matsuda, 
Lolait, Brownstein, & Young, 1990; Matusda, Lolai, Brownstein, & Young, 1990) 
and three years later, CB2 was discovered (Matsuda, Bonner, & Lolait, 1993). 
CB1 and CB2 receptors are metabotropic receptors coupled to Gi/o proteins; once 
activated, they inhibit adenylyl cyclase, close Ca2+ channels, open K+ channels, 
and stimulate kinases, which phosphorylate tyrosine, serine, and threonine 
residues on various proteins (Solinas, Goldberg, & Piomelli, 2008). 
 
The endocannabinoid system is crucial in dopamine signaling in motivated 
behavior (Oleson et al., 2012; Solinas et al., 2008). CB1 receptor activation 
mediates transient increases of dopamine in the NAc during reward seeking 
behavior (Oleson et al., 2012; Oleson & Cheer, 2012). Also, blocking CB1 
receptor attenuate drug seeking behavior not only elicited by cannabinoid agonist 
but also other abused drugs (Hernandez & Cheer, 2011). Also, increasing 
endocannabinoid tones by inhibiting degradation enhance dopamine level in the 
NAc as well as reward seeking behavior (Oleson et al., 2012). Thus, 
endocannabinoid signal in the VTA is essential to modulate dopamine release in 
coding incentive motivation. 
 
CB1 receptors located on the presynaptic axonal terminal are well-characterized 
to suppress the release of neurotransmitters such as glutamate and GABA 
(Freund, Katona, & Piomelli, 2003). Disinhibition of dopaminergic cells via CB1 
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receptor activation in the VTA is known as the core mechanism of the 
cannabinoid-induced modulation in the reward pathway. In other words, CB1 
receptor activation reduces the release of the inhibitory neurotransmitter GABA 
onto VTA neurons, thus facilitating the burst firing of dopaminergic cells, which 
subsequently results in dopamine release in the PFC and NAc (French, 1997). 
 
Cannabinoid-induced effects on the mesolimbic pathway 
 
1. Dopamine signaling in the NAc 
 
It has been established that cannabinoids increase dopamine release in the axon 
terminal of VTA dopamine neurons, as other abused drugs do. First, using 
microdialysis, Chen and colleagues reported that systemic administration of THC 
in freely moving animals increased the dopamine concentration in the NAc (Chen 
et al., 1990). A few years later, this study was successfully replicated to show 
that THC, as well as WIN 55,212, increased dopamine release in NAc and that 
this effect was blocked by the CB1 receptor antagonist, SR141716 (Tanda, 
Pontieri, & Di Chiara, 1997). Moreover, using a “real time” technique called fast 
scan cyclic voltammetry (FSCV), it was confirmed that cannabinoids enhance 
subsecond dopamine transient in the NAc of freely moving animals (Cheer, 
Wassum, Heien, Phillips, & Wightman, 2004).  
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The possible underlying mechanism of this increase of NAc dopamine would be 
an increase in the burst firing of VTA neurons by exogenous cannabinoids. The 
VTA, located in the midbrain, is composed of dopaminergic cells and non-
dopaminergic (most of them are GABAergic) cells (Lupica, Riegel, & Hoffman, 
2004). VTA dopaminergic neurons normally fire at 5-10 Hz (pace-maker firing) in 
freely moving rats (Kiyatkin & Rebec, 1997), but in response to salient stimuli, the 
firing pattern becomes bursts of about 20 Hz (Hyland, Reynolds, Hay, Perk, & 
Miller, 2002). VTA dopaminergic neurons are reported to show burst activity in 
response to rewards, including abused drugs, which results in phasic dopamine 
release in the axonal synapse (Schultz, 2007). 
 
2. VTA dopaminergic neurons 
 
CB1 receptors have been identified in both glutamatergic and GABAergic 
synapses in the VTA (Mackie, 2005; Mátyás et al., 2008). The anatomical studies 
suggests that not only can endogenous cannabinoids modulate the reward 
pathway, but also that exogenous cannabinoids can directly modulate GABA or 
glutamate release on VTA dopaminergic neurons. Along with the presence of 
CB1 receptor in the VTA, cannabinoids also modulate VTA dopaminergic 
function via indirect mechanism (Wenzel & Cheer, 2014). The VTA receives input 
from the various nuclei involved in integrating sensory information and motor 
output. Among these, three major glutamate afferents are located in the medial 
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prefrontal cortex, the pedunculopontine region, and the subthalamic nucleus 
(Melis, 2004). Also, the VTA receives major GABAergic inputs from NAc, 
mesopontine rostromedial tegmental nucleus (RMTg), and ventral pallidum 
(Lecca, Melis, Luchicchi, Ennas, Castelli, Muntoni, et al., 2011a). 
 
Endogenous as well as exogenous cannabinoids mediate the presynaptic 
inhibition of glutamate transmission in the VTA (Melis, 2004); WIN55,212 
reduced both NMDA and AMPA currents in the slice preparation of VTA 
dopaminergic neurons. The endogenous cannabinoid 2-AG also reduces the 
glutamate mediated long-term potentiation (LTP) of VTA DA neurons (Kortleven, 
Fasano, & Thibault, 2011). Thus, cannabinoid receptor activation reduces 
glutamate transmission possibly via presynaptic inhibition of glutamate release. 
However, suppression of glutamate release on VTA dopaminergic neurons in 
response to cannabinoids might contradict previous studies showing increased 
DA release after cannabinoid administration. 
 
CB1 receptor activity is highly linked to VTA dopaminergic neuronal firing via 
inhibitory afferents to these cells. The mesopontine rostromedial tegmental 
nucleus (RMTg), also known as a tail of the VTA, provides the major GABAergic 
input to the VTA (Lecca, Melis, Luchicchi, Ennas, Castelli, Muntoni, et al., 2011a). 
Cannabinoids significantly suppress RMTg activity, which is reversed by the CB1 
antagonist, SR141716 (Lecca, Melis, Luchicchi, Ennas, Castelli, Muntoni, et al., 
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2011a). The electrical stimulation of RMTg inhibits the spontaneous activity of 
VTA dopaminergic neurons (Lecca, Melis, Luchicchi, Muntoni, & Pistis, 2011b) 
suggesting that RMTg neurons are excited by aversive stimuli such as a foot-
shock and reward-omission, whereas they are inhibited by appetitive stimuli like 
reward delivery (Jhou, Fields, Baxter, Saper, & Holland, 2009). CB1 receptor 
activation by WIN55,212 attenuates RMTg-evoked suppression of VTA DA 
neuron firing as well as GABA synaptic transmission on DA neurons (Lecca, 
Melis, Luchicchi, Muntoni, & Pistis, 2011b).  
 
Given that CB1 receptor distribution in the RMTg largely unknown, two possible 
ways can be suggested in which CB1 receptors on inhibitory terminal exert their 
effect on VTA DA neuronal firing. First, lateral habenula (LHb), one of the major 
inputs to RMTg, contains a higher level of CB1 mRNA than other thalamic nuclei 
(Matsuda, Bonner, & Lolait, 1993). RMTg is heavily innervated by glutamatergic 
input from LHb (Matsumoto & Hikosaka, 2007),  cannabinoids possibly influence 
the VTA DA neurons via LHb. In fact, electrical stimulation of LHb neurons 
inhibits VTA neuronal activity (Matsumoto & Hikosaka, 2007). These results 
indicate that activation of CB1 receptors reduces the LHb glutamatergic input to 
RMTg, which attenuates inhibitory control to VTA so that the neurons are 
disinhibited.  Second, it is possible that exogenous cannabinoid bind CB1 
receptors in RMTg GABAergic terminal and reduce GABA release causing 
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disinhibition of VTA cell firing. However, like mentioned above, no information is 
available on CB1 expression in the RMTg so far. 
 
Cannabinoids can reduce both glutamate and GABA via presynaptic inhibition, 
which have opposite effects on VTA neuronal firing. Based on published data, 
disinhibition through GABAergic terminals might be more predominant than 
disinhibition through glutamatergic terminals. Also, endocannabinoid signaling in 
the VTA is required for transient increases in NAc dopamine during reward 
seeking (Oleson et al., 2012); 2-AG signaling in the VTA tightly controls the 
amount of dopamine transient in the NAc as well as reward seeking behavior. 
Thus, it is suggested that augmentation of VTA CB1 activation by synthetic 
cannabinoids positively regulate transient dopamine release by increasing VTA 
burst firing. 
 
3. NAc neuronal activity 
 
The NAc is a key neural substrate of the mesolimbic pathway that receives dense 
dopamine input from the VTA.  Transient dopamine increases in the NAc have 
been found during motivated behavior such as drug seeking behavior (e.g., 
pressing a lever for cocaine self-administration) or responding to cues for reward 
availability (Carelli, 2004). Electrophysiological recordings have revealed that 
NAc neurons change (increase and/or decrease) firing patterns in response to 
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natural reward (food) as well as abused drugs (cocaine) (for review, (Carelli, 
2004)). However, the effect of cannabinoid on NAc neuronal firing remains to be 
determined.  
 
NAc neurons are comprised of GABAergic medium spiny neurons (MSN) (more 
than 90%) and fast spiking interneurons (FSI), which are characterized by a slow 
(< 6 spikes/s) and relatively active rate (>10 spikes/s), respectively (Pennartz, 
Groenewegen, & Lopes da Silva, 1994). The MSNs directly receive dopaminergic 
input from the VTA and glutamatergic inputs from the prefrontal cortex, 
hippocampus, and basolateral amaygdala (Kalivas, 2004). The FSIs, as a 
component of local striatal microcircuits, receive efferent signals and exert their 
influence on neurons outside the NAc only through their impact on the MSNs 
(Wiltschko, Pettibone, & berke, 2010). CB1 receptors are found in fast spiking 
interneuron (FSI), projecting strong inhibition on medium spiny neuron (MSN) 
(Winters et al., 2012) as well as in MSN (Pickel, Chan, & Kearn, 2006).  
 
Moreover, the NAc consists of two heterogeneous sub-regions, the core and the 
shell, which are distinct from each other in their connections, morphology, and 
functions. Both the core and shell are densely innervated by VTA neurons; 
however, the NAc core receives glutamatergic input from the prelimbic (PL) area 
of mPFC, whereas the shell receives glutamatergic projection from the infralimbic 
(IL) are of mPFC (Sesack & Bunney, 1989). The PL-NAc core connection has 
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been found to be critical for drug relapse in response to drug paired cues, stress, 
and the drug itself (LaLumiere & Kalivas, 2008; Rogers, Ghee, & See, 2008). To 
understand the cannabinoid induced effects on PL-NAc core connection, neural 
adaptation of the NAc core was focused on throughout this dissertation. 
 
Two types of DA receptors – D1 type receptor (D1R) and D2 type receptor (D2R) 
- mediate the effects on NAc neuronal activity. In vitro study showed that 
combination of D1R and D2R agonist enhanced the NAc core neuronal firing 
(Seif, et al., 2011). Also, recent study showed that D1R and D2R differently 
modulates excitatory glutamatergic input from PL in the NAc (Wang et al., 2012); 
at low frequency of cortical activity, presynaptic D1R promote glutamate release, 
whereas postsynpatic D2R inhibit excitatory inputs. Moreover, repeated 
exposures to abused drugs (cocaine) differently modulate D1R and D2R 
containing NAc neuronal activity in terms of membrane excitability and 
morphology (Kim, Park, Lee, Park, & Kim, 2011). Thus, DA regulates NAc activity 
via two different ways, which further underlies motivated and addiction-related 
behavior.  
 
Only few studies have been done regarding neural firing patterns in the NAc in 
response to cannabinoid treatment. Single or repeated cannabinoid exposure 
could dampen the PL-NAc core glutamatergic connection (Mato, Robbe, Puente, 
Grandes, & Manzoni, 2005; Pistis, Porcu, Melis, Diana, & Gessa, 2001; Robbe, 
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Alonso, Duchamp, Bockaert, & Manzoni, 2001); these studies showed that 
cannabinoid reduced NAc neuronal spiking rate evoked by PL stimulation, major 
glutamatergic projection to the NAc core. Another in vitro study revealed that CB1 
receptor activation mediates DA receptor function of increasing NAc core 
neuronal firing (Seif, Makriyannis, Kunos, Bonci, & Hopf, 2011) implying that CB1 
activation modulates the NAc discharge in response to DA release. Moreover, 
regarding local field potential (LFP), changes in oscillations of large numbers of 
neurons, only one study showed that cannabinoid agonist, CP55,940, reduced 
LFP at 0.1–30 Hz in the hippocampus as well as power at 30–100 Hz in mPFC 
(Kucewicz, Tricklebank, Bogacz, & Jones, 2011). To the best of my knowledge, 
there has not been any study showing cannabinoid induced effects on NAc in 
vivo recording in freely moving animals under cannabinoid exposure.   
 
Neuronal changes in the mesolimbic pathway after chronic cannabinoid 
exposure 
 
Since cannabis derivatives are usually used for a prolonged time, this 
dissertation concerned with ongoing changes in the reward pathway in response 
to repeated exposure to cannabinoids. Following repeated administration, 
tolerance develops to most responses of cannabinoids including locomotor 
effects, antinociception, and hypothermia (Maldonado & de Fonseca, 2002). In 
that both synthetic cannabinoid receptor agonists and THC excite CB1 receptors 
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in the brain, the primary effects can involve prolonged stimulation of CB1 
receptors.  
 
Repeated exposure to cannabinoids causes down-regulation/desensitization of 
CB1 receptors.  The cannabinoid receptor binding using [3H] CP 55,940 was 
significantly reduced in the brain after 8 days of THC treatment including 
cerebellum, the limbic forebrain, and the striatum (Di Marzo et al., 2000). 
Moreover, WIN 55212 stimulating [35S]GTPΥ binding decreased in most brain 
areas after 8 days of treatment (Di Marzo et al., 2000) implying that cannabinoid 
tolerance is accompanied by attenuation of G-protein activity of the CB1 receptor. 
This finding is also consistent with results from human marijuana users. In the 
post-morterm brains of chronic users of marijuana, significant reduction in brain 
CB1 receptors has been reported (Villares, 2007); autoradiographic binding of 
[3H] SR141716A was decreased in the VTA and NAc of marijuana users 
compared to those of the control group.  
 
In addition, chronic cannabinoid exposure alters the structure/function of neurons 
in the reward pathway. Kolb and colleagues found that exposure to THC 
increases the length of the dendrites as well as the number of dendritic branches 
in the NAc and PFC (Kolb, Gorny, Limebeer, & Parker, 2006). Interestingly, these 
changes are restricted to NAc and mPFC, which are highly innervated by the 
VTA. Moreover, after repeated THC treatment, dopamine metabolism measured 
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by the ratio of DOPAC was decreased in the PFC but not in the NAc (Verrico, 
Jentsch, & Roth, 2003). Also, there are changes in the amount of endogenous 
cannabinoids under chronic exogenous cannabinoid treatment. Both 2-AG and 
AEA significantly decreased in the dorsal striatum, whereas only AEA showed an 
increase in the limbic forebrain, which includes the NAc followed prolonged 
exposure to cannabinoids. 
 
Thus, under prolonged exposure to cannabinoids, neuronal adaptations take 
place such as CB1 receptor desensitization and down regulation of endogenous 
cannabinoids.  There exists regional difference in the rate and degree of adaptive 
response to chronic cannabinoid exposure (Martin, Sim-Selley, & Selley, 2004). 
Moreover, neuronal changes in the reward circuit does not necessarily mean 
alteration in function; VTA neurons continued to show enhanced firing rates 
following repeated cannabinoid treatment same as the initial one (Cheer, 
Marsden, Kendall, & Mason, 2000a; Wu & French, 2000). 
 
To assess the acute and chronic effect of cannabinoid on NAc core signaling 
change, I have analyzed NAc neuronal signaling on initial and repeated exposure 
(seven daily injections) of a cannabinoid receptor agonist, CP55,940 (0.2 mg/kg 
or 0.4 mg/kg) in experiment 1. To examine dopamine dynamic under cannabinoid 
exposure, the electrically evoked dopamine overflow was collected using fast 
scan cyclic voltammetry (FSCV) in experiment 2. Using kinetic analysis, 
 14 
dopamine release and reuptake were assessed immediately following one or 
seven daily injections of CP55,940 (0.2 mg/kg, i.p.) or a vehicle. 
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Experiment 1: Neuronal firing patterns of Nucleus accumbens core in 
response to acute and chronic exposure to CP55,940 
 
In the experiment 1, the effects of cannabinoids on NAc neuronal firing patterns 
and neuronal oscillation were investigated. Since cannabis derivatives are 
usually used for a prolonged time, this study also investigated alterations in the 
NAc in response to repeated exposure to cannabinoids. To this end, the 
recording on neuronal discharge and LFPs in the NAc after single or repeated (7 
days) cannabinoid treatment was performed with in vivo electrophysiology. This 
experiment focused on changes in neuronal discharge in the NAc after single or 
repeated cannabinoid treatment to discover the influence of cannabinoids on NAc 
activity Based on previous data that have shown the cannabinoid-induced 
suppression on glutamatergic synapse of the NAc, I hypothesized that NAc 
neuronal activity would be reduced after cannabinoid exposures. Moreover, in 
that DA receptor agonist reduced striatal theta and beta oscillation (Berke, 
Okatan, Skurski, & Eichenbaum, 2004), cannabinoid exposure was expected to 
reduce slow LFP rhythms. 
 
Experimental Procedures 
 
1.Subjects 
Male Sprague–Dawley rats (n=29) weighing 250-350 g (Harlan, Indianapolis, IN, 
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USA) were housed individually and allowed at least a week of habituation before 
surgery. Rat housing maintained a 12:12 h light–dark cycle (lights were turned on 
at 9:00 am) with unrestricted water and food ad libitum. All experimental 
procedures were approved by the Institutional Animal Care and Use Committee 
at Indiana University Bloomington, IN, USA.  
 
2. Drug Administration 
Two doses (either 0.2 mg/kg or 0.4mg/kg intraperitoneal [i.p.]) of CP55,940 
(Tocris,  Bristol, UK) or the vehicle (10% ethanol, 10% cremophor, and 80% 
saline) were used for the experiment. The dose of 0.2mg/kg CP55,940 (CP0.2) 
was chosen because it induced rewarding effect measured by conditioned place 
preference (Braida, Pozzi, Cavallini, & Sala, 2001a). A higher dose of 0.4mg/kg 
CP55,940 (CP0.4) was also tested since the effect of chronic treatment of 
0.4mg/kg includes CB1 receptor reduction in the brain (Rubino, Viganò, Massi, & 
Parolaro, 2000) as well as increase in cocaine self-administration (Higuera-Matas 
et al., 2010). 
 
3. Electrode Construction and Surgical Procedures 
Electrode bundles were constructed of eight 50 um Formvar-insulated stainless 
steel wires (California Fine Wire, Grover Beach, CA, USA) and a 50 um 
uninsulated stainless steel ground wire soldered to a 10-pin connector. On the 
day of surgery, the electrode bundles were chronically implanted in the NAc core 
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unilaterally; rats were anesthetized with ketamine (80 mg/kg) and xylazine (10 
mg/kg) and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, 
USA). One hole was drilled over NAc (+1.3 anterior and ±1.3 lateral) (Paxinos 
and Franklin, 2001), and the underlying dura mater was carefully removed. Three 
additional holes were drilled for stainless steel crews. The electrode bundle was 
lowered (6.5–7.5 mm ventral) into the holes, and dental cement was used to 
cover the surgical sites. Rats were allowed at least a week for recovery from 
surgery before experimental sessions began. 
 
4. Electrophysiology 
After at least 7 days of recovery, the rats were placed into an open-field recording 
chamber (25x18 cm with outwardly angled walls 17 cm high) for two days for at 
least 30 min daily for habituation to the chamber. On the following day, the rats 
received a saline injection intended for the habituation of the i.p. injection. On the 
recording day (Day 1), each rat started receiving a daily i.p. injection of 0.2mg/kg 
or 0.4mg/kg of CP55,940 or the corresponding vehicle for 7 days. 
Electrophysiological data were collected on Day 1 and 7 of either CP55,940 
(CP0.2 or CP0.4) or the vehicle injection for acute and chronic treatment, 
respectively (Fig 2). 
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Figure 2. Timeline of experimental procedure. Electrophysiological signals 
collected on the first and seventh day of the treatment schedule (red arrow) 
following recovery from surgery. 
 
The recording session lasted for 90 min and was divided into two successive 
periods: baseline (30 min), which involved no treatment, and post-injection (60 
min), which began after an injection of the vehicle or CP55,940. Open field 
behavior was recorded for further analysis of locomotive behavior. At the 
beginning of recording, rats were placed into the recording chamber and the 
electrode assembly was connected to a lightweight flexible wire harness. The 
harness was connected to a commuter, which permitted unrestricted movement. 
Extracellular spike activity was routed through multiple-channel preamplifiers with 
154Hz–8.8 kHz band pass filters (Plexon, Dallas, Texas USA). The signals were 
digitized at 40 Hz and registered by a multichannel acquisition processor system 
(Plexon).   To be classified as single unit activity, waveforms displayed signal-to-
noise ratios of at least 2.5:1 and exhibited a consistent shape and amplitude. 
surgery 
Recovery (~ 7 days) 
 
habituation 
(3 days) 
 
Injection - 7 days 
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(single unit activity  
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Autocorrelation was used to ensure the presence of the absolute refractory 
period. Putative medium spiny neuron (MSN) were selected that showed less 
than 10 spikes/s. LFPs were routed through preamplifiers with 1,000× gain and 
0.7–170 Hz filters. At the end of the experiment, each rat was perfused for 
subsequent histological verification (Fig 3). Briefly, animals were deeply 
anesthetized and an electrical pulse (30 μA for 5 seconds) was passed through 
each microwire. Animals were perfused with saline followed by 10% potassium 
ferrocyanide in 10% formalin. Brains were removed and protected in 30% 
sucrose in 10% formalin. The brains were frozen and coronal slices (50 μM thick) 
were mounted on gelatin subbed slides to confirm the location. 
+ 1.2 mm 
Figure 3. Placement of microwire electrode bundles to the NAc core (A/P 
+1.2 mm). Coronal section of rat brain that shows the location of histologically 
verified electrode bundle placements in the NAc core (modified from Paxinos and 
Franklin, 2001). Shaded areas (NAc) cover the places where the electrode tips 
were located and number indicates distance (in mm) anterior to bregma. 
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5. Data Analysis 
Electrophysiological data were analyzed using NeuroExplorer version 4.0 (Nex 
Technologies, USA), MATLAB (The MathWorks, Inc.,USA) and GraphPad Prism 
6 (GraphPad Software, USA). A mean baseline and post-injection firing rate were 
obtained during a period of 30 min before injection and 50 min after injection, 
respectively. The period of 10 min immediately following injection was omitted 
from analysis to avoid injection-related effects. The mean baseline was 
compared using one-way ANOVA with Bonferroni multiple comparison between 
three groups. The changes in firing rates of the post-injection period compared to 
the baseline were analyzed using a paired t- test. To examine the distribution of 
responses, units that changed (increase or decrease) in firing rate >30% were 
considered to show the significant response compared to the baseline (Ball, 
Wellman, Miller, & Rebec, 2010); units showing consistent response - either >30% 
above baseline (increase) or below baseline (decrease) -  at least six consecutive 
bins (bin = 5 min) were classified to be excited or inhibited, respectively. Chi-
square tests were used to compare the distribution of three response types—
namely, inhibited, excited, and nonresponsive—among the three groups and 
within the same treatment group in acute and chronic treatment.  
 
Correlated neuronal activities were examined by building cross-correlation 
histograms (CCHs) based on 1ms bins and ± 1 s time zero bin (NeuroExplorer). 
If two neurons tend to fire at the same time more than randomly, the time lag 
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between two neurons are zero which results in a peak at zero bin in CCHs. 
Peaks that exceed the 95% confidence limit in the CCHs were considered 
correlated whereas peaks below this limit were considered non-correlated. Fig 4 
shows represented CCH matrices of non-correlated and correlated pairs (dashed 
line means 95% confidence limit). 
 
 
 
Figure 4. Representative CCHs. Y axis refers to counts/bin (bin=0.001 sec). 
The CCHs in the upper panel represent examples of ‘correlated’ pairs whereas 
the CCHs in the lower panel indicate examples of ‘uncorrelated’ pairs. 
 
 22 
Burst firing was analyzed to separate fast firing activity from regular pace making 
firing. The specific interval method was used with the following index: the 
maximum interval to start burst = 80ms, maximum interval to end burst = 160 ms, 
minimum interval between bursts = 45 ms, minimum duration of burst = 20 ms, and 
minimum number of spikes in a burst = 3 based from the previous established 
definition (Fig 5, (Gulley & Stanis, 2010; Sun & Rebec, 2006)) 
 
 
Figure 5. Diagram of burst firing analysis with specific interval methods. 
The parameters were adapted from the previous established literature (Gulley & 
Stanis, 2010; Sun & Rebec, 2006) 
 
For LFPs, power spectral density, which was normalized and represented as a 
percentage of total spectral power, was compared before and after the injection. 
Power spectral densities (PSD) were constructed in NeuroExplorer with following 
index: maximum frequency = 50Hz, Number of frequency value = 256, 
normalized by percentage of total power spectral density (PSD), smooth with 
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Gaussian filter) (Hong et al., 2012). PSDs were averaged across three groups on 
day 1 and day 7 and compared. Spectrogram generated in NeuroExplorer using 
low PSD across the time. 
 
Quantifying locomotion, a trained observer viewed DVDs of experimental 
sessions using JWathcer (University of California Los Angeles, USA). 
Locomotion was defined the time spent when animals step forward with all four 
paws moving. To assess the level of cannabinoid-induced locomotion, the time of 
locomotive activity after vehicle or CP55,940 injection was normalized to that of a 
baseline. The locomotive behavior was compared using one-way ANOVA with 
Bonferroni’s multiple comparison between three groups 
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RESULTS 
 
1. Mean Firing Rate Changes after CP55,940 treatment 
For the recording, the rats were placed in the open arena, and the baseline 
neuronal firing rate was acquired during the first 30 min prior to the injection with 
the vehicle or either dosage of CP55,950. The mean baseline firing rates (±SEM) 
were 2.51 (±0.50), 2.95 (±0.63), and 2.37 (±0.51) per second for the vehicle, 0.2 
mg/kg of CP55,940 (CP0.2), and 0.4 mg/kg of CP55,940 (CP0.4) group, 
respectively (Fig. 6; the number of neurons : vehicle = 32, CP0.2 = 28, CP0.4 = 
33). There was no significant difference across the three groups in the baseline 
firing rate tested by one-way ANOVA. However, after cannabinoid injection, firing 
rates were significantly reduced to 1.04 (±0.31) and 1.29 (±0.42) for CP0.2 and 
CP0.4, respectively (p < 0.01 and p < 0.001, paired t test), whereas the vehicle 
injection did not show any significant change in firing rates. 
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Figure 6. Effect of acute vehicle or CP55,940 treatment. Mean firing rate with 
SEM of all units on day1. Baseline (30min) and post-injection (50min) firing rates 
were compared using paired t-test,  **p<0.01, ***p<0.001 
 
Following chronic treatment (Fig 7), the baseline firing rates were not significantly 
different across the three groups (One-way ANOVA, the number of neurons: 
vehicle = 28, CP0.2 = 29, CP0.4 = 34). However, CP0.2 and CP0.4 treatment still 
showed significant reduction in the firing rate similar to acute treatment; the mean 
baseline firing rate was 2.97 (±0.68), 3.39 (±0.83), and 3.33 (±0.71) for the 
vehicle, CP0.2, and CP0.4 groups, respectively. After injection, CP0.2 and CP0.4 
significantly decreased the mean firing rate to 1.74 (±0.66) and 1.79 (±0.50), 
respectively (p < 0.001 and p < 0.01, paired t test), whereas the vehicle injection 
again did not show any significant change in firing rates. 
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Figure 7. Effect of vehicle or CP55,940 chronic treatment. Mean firing rate 
with SEM of all units on day 7. Baseline and post-injection firing rates were 
compared using paired t test, **p<0.01, ***p<0.001 
 
2. Distributions of Inhibited, Excited, or Non-responsive Units 
Units showing either consistent increases or decreases in firing rate >30% from 
the baseline for at least six consecutive five minute bins (30 min) were classified 
as either excited or inhibited, respectively. Following to acute treatment, most 
neurons (86% and 76% of the total units for CP0.2 and CP0.4, respectively) 
showed significantly inhibited responses, whereas 60% of neurons were non-
responsive to the acute vehicle treatment (Fig. 8). Chi square test confirmed the 
significant differences in neuronal response (χ2 = 69.31, df =4, p<.0001).  The 
acute vehicle group showed significant difference compared to CP0.2 and CP0.4 
(CP0.2: χ2 = 56.72, df =2, p < 0.0001; CP0.4 χ2 = 37.04, p < 0.0001). The 
responses of the two cannabinoid-treatment groups did not show any significant 
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differences in the distribution of responsive units, which implies that the two 
different doses caused similar effects on neuronal response. 
 
 
Figure 8. Distribution of excited, inhibited and non-responsive neurons 
following acute vehicle or CP55,940 treatment Chi statistic shows there are 
significant differences between control vs. CP0.2 and control vs. CP0.4 
(p<.0001). No significant difference in unit distribution between CP0.2 and CP0.4  
 
Following the seventh injection of the vehicle or either CP0.2 or CP0.4 (Fig. 9), 
the responses of most neurons shows similar pattern compared to acute 
treatment; the majority of neurons in CP0.2 and CP0.4 showed inhibited 
response (68% and 71%, respectively), whereas 79% of neurons in the vehicle 
treated groups showed non-responsive. Also, chronic treatment of cannabinoid 
still caused different neuronal response compared to the vehicle treatment (χ2 = 
72.02, p < 0.0001 for CP0.2; χ2 = 78.05, p < 0.0001 for CP0.4). No significant 
difference in distribution of responses between two cannabinoid groups on Day 7.  
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Within the same treatment group, the prolonged treatment of the vehicle or 
CP0.2 changes in distribution of neuronal response compared Day 1 with Day 7 
(χ2 = 18.13, p = 0.001 for the vehicle; χ2 = 9.147, p < 0.01 for CP0.2). Treatment 
of CP0.4 showed the same response. 
 
 
Figure 9. Distribution of excited, inhibited and non-responsive neurons 
following chronic vehicle or CP55,940 treatment. Chi statistic shows there are 
significant differences between control vs. CP0.2 and control vs. CP0.4 
(p<.0001). No significant difference in unit distribution between CP0.2 and CP0.4.  
 
3. Response of NAc neurons across time after injection 
In response to the acute treatment, the mean firing rate of all units significantly 
decreased compared to the baseline by 46% and 59% for CP0.2 and CP0.4, 
respectively, after 16–20 min post-injection (Fig. 10). After 20 min post-injection, 
the mean firing rate was reduced by 80% and 70% for CP0.2 and CP0.4, and the 
changes in magnitude remained significantly decreased compared to the vehicle 
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treatment. One-way ANOVA with Bonferroni multiple comparisons test revealed 
that % of baseline of three groups were significantly different after 16 min of 
injection and the differences were from CP0.2 vs. vehicle and CP0.4 vs. vehicle. 
Difference between CP0.2 and CP0.4 were not significant at any time bin. 
 
 
 
Figure 10. Magnitude of response for mean firing rate after acute vehicle or 
CP55,940 treatment. Curves represent mean (+SEM) firing rate normalized to 
pre-injection baseline activity for each 5-min bin beginning 10 min after CP55,940 
(or vehicle) injection on Day1. Averaged response of all recorded units showed 
significant reduction after CP55,940 compared to vehicle (one-way ANOVA). 
Between CP0.2 vs. CP0.4 there were not significant differences. (** p<.01, 
***p<.001) 
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Table 1. The magnitudes of firing rate changes compared to the baseline (% 
of baseline) across time in acute treatment. The average ± SEM 
 
vehicle CP0.2 CP0.4 
11-15 min 72.80 ± 8.35 90.50  ± 20.16 81.78 ± 14.25 
16-20 min 72.80 ± 8.09 46.32 ± 8.89 59.69 ± 9.11 
21-25 min 85.77 ± 13.52 26.34 ± 5.81 44.36 ± 6.48 
26-30 min 93.62± 9.64 25.79 ± 5.43 45.86 ± 7.74 
31-35 min 91.24 ± 9.37 23.71 ± 5.33 49.84 ± 10.57 
36-40 min 85.39 ± 8.26 24.79 ± 5.02 41.7 ± 8.8 
41-45 min 74.46 ± 9.83 21.54 ± 4.75 41.09 ± 9.48 
46-50 min 82.02 ± 7.84 30.6 ± 6.85 38.23 ± 9.01 
51-55 min 77.16 ± 13.60 21.04 ± 4.62 34.62 ± 5.85 
56-60 min 81.48 ± 8.49 21.14 ± 4.38 34 ± 7.14 
! ! ! ! ! 
Following the chronic treatment, the patterns were same as those of the acute 
treatment (Fig. 11). Average single unit activity remained inhibited by about 40–
50% (compared to the baseline) at 10 min after injection CP0.2 or CP0.4 (Table 
2). One-way Anova with Bonferroni test (multiple comparisons) revealed that % 
of baseline of three groups were significantly different after 11 min of injection 
and the differences are from CP0.2 vs. vehicle and CP0.4 vs. vehicle. 
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Figure 11. Magnitude of response for mean firing rate after chronic vehicle 
or CP55,940 treatment. Curves represent mean (+SEM) firing rate normalized to 
pre-injection baseline activity for each 5-min bin beginning 10 min after CP55,940 
(or vehicle) injection on Day7. Averaged response of all recorded units showed 
significant inhibition after CP55,940 similar to Day 1. *p<.05, **p<.01, ***p<.001 , 
one way ANOVA with Bonferroni’s multiple test. 
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Table 2. The magnitudes of firing rate changes compared to the baseline (% 
of baseline) across time in chronic treatment. The average ± SEM 
 
vehicle CP0.2 CP0.4 
11-15 min 145.26 ± 33.57 49.73 ± 6.66 69.93 ± 15.18 
16-20 min 121.65 ± 20.33 44.44 ± 6.97 52.58 ± 8.91 
21-25 min 125.93 ± 18.71 43.02 ± 6.55 56.20 ± 11.77 
26-30 min  89.65 ± 12.71 39.71 ± 6.17 56.05 ± 11.96 
31-35 min 90.60 ± 15.33 40.34 ± 6.19 60.80 ± 20.15 
36-40 min 90.58 ± 15.50 38.75 ± 5.49 37.62 ± 6.14 
41-45 min 98.74 ± 14.76 42.35 ± 7.09 50.31 ± 16.04 
46-50 min 102.88 ± 18.79 39.97 ± 7.02 37.62 ± 6.60 
51-55 min 101.36 ± 16.52 42.79 ± 9.02 33.99 ± 7.58 
56-60 min 115.47 ± 25.89 42.41 ± 7.87 40.65 ± 8.07 
 
To compare the response between acute and chronic treatment of CP55,940, 
response of each bin (5 min) on day1 was compared to the same bin on day7 
using t-test. Acute treatment of 0.2mg/kg of CP55,940 significantly inhibited the 
firing rates more than chronic treatment (Fig 12 (a); 21-25, 31-45, 55-60 min after 
the injection showed significant reduction on acute treatment compared to the 
chronic treatment, p<.05). However, 0.4mg/kg of CP55,940 treatment showed 
consistent response on both acute and chronic treatment (Fig 12 (b)). 
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Figure 12.Magnitude of neuronal responses of CP0.2 (a) and CP0.4 (b) in 
response to acute or chronic treatment. Neuronal responses after acute 
treatment and chronic treatment were compared using t-test. (a) In CP0.2 group, 
acute treatment showed significant reduced neuronal firing activity compared to 
(a)
(b)
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chronic treatment (*p<.05). (b) CP0.4 group showed no significant difference 
between acute and chronic treatment.   
 
4. Cross-correlated firing 
Correlated neuronal activities were examined by building cross-correlation 
histogram (CCH). The CCHs were constructed for all pair-wise comparisons 
within each recording session. If two neurons tend to fire at the same time more 
than randomly (Fig 13), the time between two neurons are zero which results in a 
peak at zero in CCHs. Peaks that exceed the 95% confidence limit in the CCHs 
were considered correlated whereas peaks below this limit were considered non-
correlated (two neurons fire independently).  
 
 
Figure 13. Example of rasters from one pair of neurons (units). Cross-
correlation highlighted in grey and occurs two neurons fire together. 
 
Before the injections, 50%, 48%, and 49% of pairs showed correlated activities in 
vehicle, CP0.2, and CP0.4 group respectively (total number of pairs: vehicle = 40 
pairs; CP0.2 = 46 pairs; CP0.4 = 45 pairs). However, in response to the initial 
injection of CP55,940, the proportion of correlated pairs were significantly 
decreased by 33% and 29% for CP0.2 and CP0.4 respectively (Fisher’s exact 
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test; p<.05 for CP0.2 and p<.01 for CP0.4) whereas vehicle injection slightly 
changed it by 45% (Fig 14).  
 
 
Figure 14. Change in proportion of correlated pairs following acute vehicle 
or CP55,940. The proportion of correlated pairs were significantly decreased 
after the injection of cp0.2 and cp0.4 compared to the baseline on day 1 (Fisher’s 
exact test. *p<0.5 for cp0.2 and **p<.01 for cp0.4) 
 
On seventh day of the injection, the patterns remain similar (Fig 15). The 44% 
(vehicle), 41% (CP0.2) and 43% (CP0.4) of pairs show correlated neuronal firing 
before the injection (total number of pairs: vehicle = 46 pairs; CP0.2 = 61 pairs; 
CP0.4 = 56 pairs). During the post-injection period, 50% of paired neuron in 
vehicle group showed correlated activity whereas only 21% (CP0.2) and 27% 
(CP0.4) showed correlated, which is significantly reduced compared to the 
baseline (Fisher’s exact test; p<0.1 for CP0.2 and p<.05 for CP0.4). 
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Figure 15. Change in proportion of correlated pairs following chronic 
vehicle or CP55,940. The proportion of correlated pairs were significantly 
decreased after the injection of cp0.2 and cp0.4 compared to the baseline on day 
7 (Fisher’s exact test; p<0.1 for cp0.2 and p<.05 for cp0.4) 
 
 
 
5. Burst firing rate 
 
Burst firing (see Fig 16 for a representative example) was measured using the 
specific interval algorithm on day 1 and day 7. The burst rates (bursts/min) and % 
of spikes in bursts were calculated.  
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Figure 16. Representative examples of burst firing in four different 
neurons. The gray shading and blue lines indicate bursts in each spike raster 
 
The burst firing rates in baseline were not significantly different across three 
groups on day 1 (Fig 17; the mean burst rate (bursts/min ± SEM) was 11.85 (± 
2.83) for vehicle; 15.35 (± 3.63) for CP0.2; 12.17 (± 3.25 for CP0.4). (Statistically 
not significant (n.s.) in one way ANOVA analysis). After the acute injection, the 
burst rates of CP0.2 and CP0.4 were significantly decreased to 5.22 (±1.98) and 
6.40 (± 2.20), respectively whereas that of vehicle (9.31± 2.47) was not 
significantly changed (paired t-test; p<0.01 for both CP0.2 and CP0.4). 
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Figure 17. Burst rate per minute following acute vehicle or CP55,940. The 
baseline burst rate was compared with one-way ANOVA across three groups 
(n.s.) and paired t-test was performed to compare the change within each group. 
**p<.01 
 
Moreover, the percentage of spikes in burst firing was compared before and after 
the injection. About one third of total neuronal spikes were categorized as burst 
firing during the baseline period and there was no significant group differences 
using one way ANOVA on day 1 (Fig 18); 34.89 (± 4.55)% for vehicle, 42.33 (± 
4.55) for CP0.2 and 34.16 (± 4.02). However, after the injection, CP0.2 and 
CP0.4 group showed significant reduction on day 1 whereas vehicle group did 
not show any significant difference (paired t-test; p<.01 for both CP0.2 and CP0.4 
group, n.s for vehicle group; the percentage of spikes in burst = 33.57 (± 4.27) for 
vehicle, 30.02 (± 4.28) for CP0.2 and 21.54 (± 4.03) for CP0.4.  
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Figure 18. Percentage of spikes in burst firing following acute vehicle and 
CP55,940. Paired t-test was performed within each group. **p<.01 
 
On seventh day (Fig 19), the baseline burst rates are not different across three 
groups tested by one way ANOVA (bursts/rate ± SEM; 13.84 ±3.65 for vehicle, 
15.98 ±4.17 for CP0.2, 16.35 ± 3.91 for CP0.4 ; the number of neurons : vehicle 
= 28, CP0.2 = 29, CP0.4 = 34). Similar to the response of day 1, CP55,940 
injection significantly reduced the burst rate whereas vehicle did not; the mean 
burst rate decreased to 7.32 (± 3.28) for CP0.2 and 9.65 (± 3.33) for CP0.4, and 
11.58 (± 3.19) for vehicle. (paired t-test; p<.01 for both of CP0.2 and CP0.4).  
 
vehicle CP0.2 CP0.4
0
10
20
30
40
50
%
 o
f s
pi
ke
s 
in
 b
ur
st
s baseline
post-injection
** **
 40 
 
Figure 19. Burst rate per minute following chronic vehicle or CP55,940.  
The baseline burst rate was compared with one-way ANOVA across three groups 
(n.s.) and paired t-test was performed to compare the burst rates within each 
group. **p<.01 
 
Moreover, the percentage of spikes in bursts on day 7 showed similar patterns as 
day 1 (Fig 20); the baselines of three groups were 36.25 (± 4.83) for vehicle 
group, 37.58 (± 5.22) for CP0.2 group and 37.18 (± 5.19) for CP0.4 group 
(statically not significant). After the injections, the percentage of spikes dropped 
to 19.56 (± 4.69) and 26.47 (±4.85) for CP0.2 group and CP0.4 group, 
respectively whereas it remained similar to the baseline for the vehicle group 
(37.05 ± 4.77). (paired t-test, p<.0001 for CP0.2 and p<.01 for CP0.4) 
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Figure 20. Percentage of spikes in burst firing following chronic vehicle or 
CP55,940. Paired t-test was performed within each group. **p<.01, ****p<.001 
 
6. Local field potentials 
 
Power spectral densities (PSD) were normalized by percentage of total PSD and 
smoothly with Gaussian filter (filter width =3) (NeuroExplorer). The percentage of 
total PSD was averaged on the subjects in the same group and the % of PSD of 
the baseline and post-injection were compared using independent t-test with 
Bonferroni correction. 
 
In response to vehicle treatment, the averaged % PSD of baseline was not 
significantly different to that of post-injection period (Fig 21 (a)(b)). For both 
CP0.2 and CP0.4 group, the power on theta spectrum (4-8 Hz) increased after 
the acute injection compared to baseline (Fig 21 (c),(e)). Following chronic 
treatment, dominance in theta band disappeared in CP0.4 group but CP0.2 
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showed higher PSD at 5-5.8 Hz compared to baseline (Fig 21 (d), (f)). In addition 
to the theta band, PSD at 1.3-2Hz showed higher densities after acute CP0.4 
treatment (Fig 21 (e)). Spectrogram showed similar density in baseline and post-
injection after chronic treatment of CP0.4 (Fig 21 (f)). 
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Figure 21. Mean Power Spectral Density (PSD) plots of vehicle (a)(b), CP0.2 
(c)(d) and CP0.4 (e)(f) group. Mean percentage of total PSD was calculated 
(solid line = mean, dotted line = SEM) following acute or chronic treatment in 
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each condition. Black arrows mark the frequency peaks that showed significant 
group differences (independent t-test with Bonferroni correction). 
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Figure 22. Examples of spectrogram after acute and chronic treatment with 
vehicle (a)(b), CP0.2 (c)(d), and CP0.4 (e)(f); Left panels indicate acute 
treatment ((a)(c)(e)) and right panels indicate chronic treatment ((b)(d)(f)). Time-
frequency plots show changes in power spectral density (PSD) in vehicle, CP0.2 
(a)vehicle (acute) (b)vehicle (chronic)
(c)CP0.2 (acute)
(e)CP0.4 (acute)
(d)CP0.2 (chronic)
(f)CP0.4 (chronic)
 46 
and CP0.4 groups. Animals received injection of vehicle or CP55,940 at 30 min 
(white dotted line). The theta rhythms showed greater spectral power density 
after acute cannabinoid treatment. 
 
7. Locomotion 
 
The doses used in this study significantly suppressed locomotor activity after 
acute treatment; Acute injection of P55,940, both 0.2mg/kg and 0.4mg/kg, 
significantly reduced locomotor activity compared to vehicle (p<.01, one way 
ANOVA, Fig 23 (a)). However, this cannabinoid-induced decrease in locomotion 
was no longer present after chronic treatment (Fig 23 (b)). The levels of 
locomotion of CP0.2 and CP0.4 were not significantly different from chronic 
vehicle. 
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Figure 23. Locomotion after acute treatment (a) and chronic treatment (b). 
(a) Both CP0.2 and CP0.4 showed significantly reduced locomotor activity after 
acute injection (one way ANOVA with Bonferroni’s multiple comparisons test 
(*p<.05, **p<.01).  (b) No significant differences across three groups (one way 
ANOVA). 
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Discussion 
 
The experiment 1 showed that CB1/2 receptor activation by CP55,940 inhibited 
NAc neuron activity supporting the hypothesis. This inhibition in neuronal activity 
appeared about 10 min after the cannabinoid injection, and the magnitude of 
inhibition was about 40-50% of the baseline. This inhibition in firing rates was 
also found after seven days of repeated CP55,940 treatment; the chronic 
treatment of 0.2 mg/kg CP55,940 slightly attenuated the inhibition, but NAc 
neurons still showed significant reduction in firing rates compared to vehicle 
treatment. Moreover, the chronic 0.4 mg of CP55,940 treatment maintained the 
consistency of inhibited response on the initial treatment. 
 
The results of the present experiment also indicate that cannabinoid treatment 
reduced bursts and correlated activity between NAc neurons. Burst spikes 
increase the chance of triggering post-synaptic transmission (Izhikevich, Desai, & 
Walcott, 2003). Moreover, correlative neuronal activity implies that they are in the 
same receptive field-overlap of presynaptic neurons (Salinas & Sejnowski, 2001). 
Thus, both changes in bursts and correlative activity may explain alteration in 
functional communication between adjacent neurons. The reduction in bursts as 
well as correlative neural activity observed in this study may imply decreased 
functional connection, as well as disrupt information processing within NAc. 
However, in the present study, the reduction in correlated and burst firing is also 
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likely due to the decrease in firing rate, relative to the baseline. Since the 
probability of correlated firing increases in spike trains with higher firing rates (B. 
R. Miller, Walker, Shah, Barton, & Rebec, 2008), decrease in correlated neuronal 
activity may possibly due to the reduction in neuronal firing rates. 
 
The possible underlying mechanism of reduction in firing rates as well as the 
correlated and bursts activity of NAc might be due to the cannabinoid-induced 
inhibitory input to the NAc core. In other words, the overall output of cannabinoid-
induced presynaptic regulation on the NAc core neurons potentially lowered 
neuronal excitability. For this, the inhibition of excitatory input (i.e., glutamate 
release) was presumably involved. The anatomical evidence that CB1 receptors 
were mostly found in the excitatory presynaptic dendrite in the NAc (Pickel, 
Chan, Kash, Rodríguez, & Mackie, 2004), instead of the inhibitory presynaptic 
synapses, could support these results. Thus, cannabinoids influence neuronal 
activities mainly by reducing excitatory input to the NAc, which is consistent with 
its anatomical distribution.  
 
Medium spiny neurons in the NAc are mostly GABAergic neurons and they 
provide an inhibitory projection to the VTA (Kalivas, Churchill, & Klitenick, 1993).. 
The reduction in inhibitory NAc input to the VTA might play a role in increasing 
VTA neuronal excitability. The present finding of steady NAc firing inhibition 
under chronic cannabinoid treatment also supports previous studies (Cheer, 
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Marsden, Kendall, & Mason, 2000a; Wu & French, 2000) that showed 
consistently enhanced VTA neuronal firing after repeated cannabinoid 
administration. Taken together, it can be expected that persistent NAc core 
neuronal signaling can be involved in the development of tolerance in the 
mesolimbic pathway. 
 
Interestingly, inhibited NAc neuronal activity in the present study is consistent to 
the NAc neuronal activity in response to rewarding stimuli. Previous research 
showed that NAc neurons were primarily inhibited by rewarding stimuli and 
excited by aversive stimuli (Carelli & West, 2014; Roitman, Wheeler, & Carelli, 
2005; Wheeler et al., 2008). Their findings indicated that most NAc neurons 
showed inhibited firing rates in response to palatable (sweet solution) stimuli, but 
they showed an excited response after aversive stimuli (quinine). Moreover, the 
degree of inhibition lessened after the devaluation of the same natural reward 
stimuli by cocaine, the drug of abuse (Carelli & West, 2014; Wheeler et al., 2008). 
The results of these studies implied that NAc neurons innately encode the 
rewarding value and that the degree of inhibition may be correlated to its 
rewarding value. The present study may provide evidence the potential 
involvement of the endocannabinoid system on encoding rewarding value by 
altering NAc neuronal signal. 
 
Moreover, inhibited NAc neuronal signaling was also found during intracranial 
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self-stimulation (ICSS) (Cheer, Heien, Garris, Carelli, & Wightman, 2005). In 
response to stimulation of medial forebrain bundle (MFB), NAc neurons showed 
inhibited response accompanying with dopamine release evoked by the 
stimulation. Even though the neuronal changes were tightly time-locked to 
dopamine release, NAc responses showed only subtle modulated by dopamine 
release but directly changed by GABA release (Cheer, Heien, Garris, Carelli, & 
Wightman, 2005). This study implies that dopamine in NAc may be involved in 
the modulation in NAc neuronal activity, but GABA release predominantly 
modulates it. Thus, it can be postulated that inhibited response found in this 
experiment may be direct effect of prefrontal input (glutamate) or local 
microcircuit (GABA) rather than input from VTA dopamine. 
 
Regarding LFPs, the results showed that the power of theta rhythm was 
augmented after acute treatment of CB receptor activation, and this effect 
diminished after chronic cannabinoid treatment. Interestingly, the theta rhythm of 
the ventral striatum responded to the reward process, especially the learning 
place-reward relationship (van der Meer & Redish, 2011). Moreover, the theta 
rhythm of the NAc core showed a tight association with the theta rhythm of the 
hippocampus formation, which encodes and retrieves memory. Anatomical 
evidence of hippocampal projections to the NAc core also supported the 
functional connection. Based on these results, increased theta rhythm after acute 
CP55,940 may indicate an active learning process that associates place and 
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reward (cannabinoid effect) information. Moreover, diminished theta rhythm after 
seven days of injection may implicate a different learning phase, in which 
presumably a hippocampal-dependent encoding process might be less involved.  
Disruption of the prefrontal theta rhythm was also implicated in increased positive 
symptoms in schizophrenia under cannabinoid exposure (Morrison et al., 2011). 
This EEG study showed that oral THC altered the prefrontal theta rhythm, 
however, did not decrease power, but the disruption of coherence (correlation of 
a specific band between the electrodes) that can be an indicator of positive 
symptoms. Another study showed that the LFP of hippocampus and prefrontal 
cortex under cannabis exposure showed reduction in theta rhythm in rats 
(Kucewicz, Tricklebank, Bogacz, & Jones, 2011); the decreased hippocampal 
theta rhythm was connected to impaired working memory. Even though the 
power of the theta band increased in the NAc core, instead of decreasing as it did 
in other studies of the hippocampus and prefrontal cortex and the hypothesis, the 
changes in theta band could be implicated in altered neuronal functions derived 
from cannabinoid exposure. 
 
Moreover, the present results suggest disassociation between neuronal activity 
and LFPs. Although CB receptor activation reduced NAc neuronal activities, it 
augmented the power of the theta rhythm in the same area. Moreover, with the 
CP55,940, the effect on neural activity lasted for one week during treatment. 
However, the cannabinoid-induced effect diminished in LFP theta rhythms during 
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the same time period.  Moreover, CP55,940 inhibited locomotor activity after 
acute treatment and this cannabinoid induced decrease disappeared after 
chronic treatment. The cannabinoid-induced suppression in locomotion as well as 
tolerance development is consistent to previous behavioral studies (for review, 
Lichtman & Martin, 2005). In that theta rhythm of hippocampus encodes 
locomotion (Ledberg & Robbe, 2011), it is speculated that theta rhythm of NAc 
core is also possibly involved in locomotion. The tolerance development in both 
locomotion and NAc theta rhythm also could explain possibly connection 
between NAc LFP and behavior. 
 
LFP, measurement of the extracellular current fields, was found more difficult to 
interpret than the activity of a single unit (Einevoll, Kayser, Logothetis, & Panzeri, 
2013). Any transmembrane current (all ionic processes) from multiple sources 
and various properties of brain tissues contributes LFPs (Buzsáki, Anastassiou, 
& Koch, 2012). Although the summation of the synaptic transmembrane current 
(action potential) mainly affects LFPs, any inward current (and returning current) 
through ligand- or voltage-gated channels from the dendrites and axon terminals 
at the proximate site of the electrode also contribute to the power of LFPs 
(Einevoll et al., 2013).  
 
LFP is continuous slower fluctuation in which the effects of the excitatory input 
(Na+ and Ca+) and inhibitory input (Cl-) do not clearly show opposite effects. For 
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example, the neurotransmitters acting on NMDA receptor and AMPA receptor 
mediate the excitatory current (from extracellular into intracellular), creating both 
an inward current and an outward (passive) current to back up the ion pool 
leading in the opposite direction of the extracellular field. However, the inward 
current of ligand on GABA receptors can create the same effect of a passive 
current of excitatory neurotransmitters (Einevoll et al., 2013). Moreover, the 
different currents from different origins can cause the same effects on LFP power. 
Even more difficult to understand is that the geometric factor (the distance 
between the electrode and the origin of current change) changes the magnitude 
of LFP power in an inversely proportional way. Thus, LFP is more difficult to 
interpret than neuronal activity because of this complexity and ambiguity.  
 
In conclusion, this dissertation study characterizes the activity of NAc core 
neurons in response to cannabinoid exposures. The present study provides 
evidence that NAc neurons primarily exhibited inhibited response under 
cannabinoid exposures with increased theta rhythm. Even though the response 
of single unit activity remained inhibited after repeated exposure, local field 
potentials changed under chronic exposure, suggesting that a separate 
mechanism was involved.  
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Experiment 2:  Dopamine dynamics of NAc core in response to acute and 
chronic exposure to CP55,940  
 
A phasic dopamine release, induced by burst firing of VTA dopaminergic neurons, 
mediates drug-related rewarding effects. Although acute cannabinoid 
administration increases spontaneous phasic DA transients in a dose-dependent 
manner (Cheer, et al., 2004), the previous results showed that VTA neurons 
could show enhanced firing rates after repeated cannabinoid treatment as being 
the same as the initial one (Cheer, et al., 2000; Wu & French, 2000). Therefore, it 
was expected that the electrically evoked DA release would increase in response 
to acute cannabinoid exposure and that this increase would remain unchanged 
after chronic exposure. However, the NAc dopamine signal in response to 
chronic cannabinoid exposure has not yet been elucidated. Moreover, 
cannabinoid effects on dopamine reuptake have brought mixed results; for 
example, cannabionoids inhibited dopamine reuptake in some studies (Pandolfo 
et al., 2011; Price et al., 2007) but failed to alter dopamine reuptake level (Cheer 
et al., 2004; Köfalvi et al., 2005). 
 
Fast scan cyclic voltammetry (FSCV) technique enabled to measure evoked 
dopamine signals with sub-second temporal resolution. Moreover, FSCV 
measuring electrically stimulated dopamine overflow in anesthetized rats has 
been used extensively to characterized dopamine uptake and release (Addy, 
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Daberkow, Ford, Garris, & Wightman, 2010) because kinetic analysis on release 
and reuptake cannot be performed without electrically stimulated dopamine. 
Using FSCV to monitor evoked dopamine overflow, dopamine dynamics in the 
NAc core - dopamine release as well as reuptake- were investigated to determine 
the effect of cannabinoid exposure. 
 
 
Experimental Procedures 
 
1.Subjects 
Male Sprague–Dawley rats (n= 10) weighing 250-350 g (Harlan, Indianapolis, IN, 
USA) were housed individually and allowed at least a week of habituation before 
surgery. Rat housing maintained a 12:12 h light–dark cycle (lights were turned on 
at 9:00 am) with water and food ad libitum. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee at Indiana 
University in Bloomington, IN, USA.  
 
2. Drug Administration 
The dose of 0.2mg/kg CP55,940 was selected since it induced rewarding effect 
measured by conditioned place preference (Braida et al., 2001a). 0.2 mg/kg of 
CP55,940 (Tocris,  Bristol, UK) or the vehicle (10% ethanol, 10% cremophor, and 
80% saline) were used for intraperitoneal [i.p.] injection.  
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3. Surgery 
To prepare carbon fiber electrodes, a carbon fiber (7 μm in diameter, T650, 
Cytec, Woodland Park, NJ) was aspirated to a glass capillary (1.0 mm diameter, 
A-M Systems, Inc., Carlsborg, WA, USA) and pulled using a vertical micropipette 
puller (Narishigee, Tokyo, Japan). Under a dissecting microscope, a scalpel was 
used to trim the carbon fiber to a length of 120 to 150 µM from the seal of a glass 
and carbon fiber. The electrodes with a low background noise (the ratio of noise 
over the background current less than 0.001) and good shape in oscilloscope 
were selected and cycled with 60Hz for at least 10 minutes. A reference 
electrode, AgCl, was prepared from pure silver wire (0.016 inch in diameter, 
Scientific Instrument Services, Inc., NJ).  
 
For the in vivo voltammetry recording, surgery was performed on the first day of 
injection (acute injection group) or the seventh day of injection (chronic injection 
group). The acute group (n=4) received a single injection of vehicle followed by 
an injection of CP55,940; the chronic group(n=6) received one daily injection for 
seven consecutive days.  
 
On the day of surgery, rats were anesthetized with ketamine (80 mg/kg) and 
xylazine (10 mg/kg) and placed in a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA, USA). Once the animal was mounted in the sterotaxic frame, an 
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incision from the anterior to the posterior of the skull was made, and the skin and 
fascia was removed to allow for a clear visual of the anatomical structures 
bregma and lambda. One hole was drilled over NAc core (+1.3 anterior and +/-
1.3 lateral), and the underlying dura mater was carefully removed. Another hole 
was drilled over the medial forebrain bundle (MFB;-4.0 anterior and +/-1.4 lateral) 
on the ipsilateral hemisphere of the working electrode placed. A hole for the 
reference electrode was made in the contralateral hemisphere of the brain.  
 
4. Data Acquisition  
Tar Heel CV software (ESA Biosciences, Inc., Chelmsford, MA) was used to 
generate a triangular waveform, which ramp between -0.4V to +1.3V at a rate of 
300V/S, was applied every 10ms. A house built potentiostat that controls signal 
transduction to a carbon fiber working electrode passes a voltage ramp to a 
carbon fiber electrode and measure the current at a respect to the Ag/AgCl 
reference electrode. The current change at the electrode compared to the 
reference electrode was plotted against applied potential (-0.4 to +1.3V). 
Dopamine is oxidized (lost two H+ ions) approximately at +0.6V to ortho-quinone 
and it reduced back to dopamine approximately at -0.2V. The current change at 
the dopamine oxidation peak (~+0.6V) was represented to dopamine signal. 
For the data acquisition, the reference Ag/AgCl electrode was placed at the hole 
touching to the surface of brain tissue. Then the working electrode was lowered 
into the NAc core; first, the electrode was lowered into 1 mm above the NAc core 
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and the electrode was cycled at 10Hz for 5 minutes and then targeted to the NAc 
core (-6.5~7.5mm below the brain surface). Finally, the biphasic-stimulating 
electrode (Plastic One, Roanoke, VA, 1 mm apart) was lowered to the top of the 
MFB (-6.5 to ~7.5 below dura). Electrical stimulation was applied (24 pulses, 
60Hz, 300 μA) while stimulating electrode was optimally placed along the dorsal-
ventral axis. The MFB was located at 1-1.5 mm below the point at which showed 
a weak whisker and/or foot twitch. Once stimulation parameters were optimized, 
the biphasic (24 pulses, 60Hz, 300 μA) stimulation was applied every 2 min.   
 
For the acute group, five consecutive trials were averaged to represent the 
evoked dopamine concentration in the baseline state (pre-treatment).  After that, 
vehicle was injected another five consecutive trials were averaged to represent 
the evoke dopamine concentration in response to acute vehicle injection. The 
same group of animals of the vehicle injection received 0.2 mg/kg of CP55,940.  
Five consecutive trials were averaged every 10 min and the highest averaged 
current was selected to represent the evoke dopamine concentration after the 
CP55,940 injection.  
 
For chronic vehicle or CP55,940 group, same as the acute group, five 
consecutive trials were averaged to represent the evoked dopamine 
concentration in the baseline state (pre-treatment). After that, animals, who 
received six days of vehicle (chronic vehicle group) or CP55,940 injections 
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(chronic CP55,940 group), received the seventh injection of vehicle or CP55,940, 
respectively. Five consecutive trials was averaged every 10 min and the highest 
averaged current was selected to represent the evoke dopamine concentration 
after the CP55,940 injection. 
 
5. Post Calibration of the electrode 
The current amplitude in vivo is considered to be proportional to the 
concentration of dopamine. The evoked dopamine concentration was calculated 
with either direct post-calibration or post-calibration curve. For the post-
calibration, immediately after the data acquisition, the electrode was carefully 
removed from the rat brain and was placed in the Tris buffer (12 mM tris–HCl, 
140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4, 1.2 mM MgCl2, 
2 mM NaSO4, pH = 7.4) for post-calibration. In a flow cell system, Tris buffer was 
constantly streamed and the switch for the 1 μM dopamine was manually on/off.  
The voltammetric signal of the pulse of 1 μM dopamine was obtained (Fig 24). 
The current (represented in color) was plotted against the applied voltage (-0.4 to 
1.3V) and dopamine was detected at its oxidation peak (~+0.6V, green color) 
during the electrode was exposed to dopamine solution. The voltammogram (Fig 
24, right panel) showed that the chemical signature of dopamine which oxidized 
at ~+0.6V and reduced at ~-0.2V. Further, the signal was transited to the 
concentration using the current/concentration ratio to calculate the evoked 
dopamine concentration on the electrode. The post-calibration curve was also 
 61 
used to convert dopamine current to concentration. For the post-calibration curve, 
the background known dopamine concentration were plotted and the estimated 
linear response was calculated.  
 
 
Figure 24. An example of color plot (left) and cyclic voltammogram (right) 
of dopamine solution in the flow cell system.  In the color plot, x-axis 
represents time (s), the y-axis represents applied potential to the electrode (V) 
and current was shown in color (nA, scale on right). The electrode was exposed 
for ~ 10 s and dopamine was detected at its peak of oxidation (~ +0.6 V, dashed 
white line). Cyclic voltammogram showed the chemical signature of dopamine 
that is oxidized at ~+0.6V and reduced at ~-0.2V.  
 
 
6. Data Analysis 
- Dopamine concentration 
The percentage change compared to the baseline (% of baseline) were 
calculated in response to the injection of CP55,940 or vehicle. An independent 
samples t-test was performed to compare the evoked dopamine concentration (% 
of baseline) between vehicle and CP55,940 treatment. One-way ANOVA with 
Bonferroni’s multiple comparisons was performed to compare the baseline 
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evoked dopamine concentration of the three conditions; acute group (no 
treatment), chronic vehicle, and chronic CP55,940. 
 
-Mathematical modeling  
Dopamine release and reuptake were estimated from Michaelis-Menten kinetics 
and exponential fit modeling developed by Demon Voltammetry analysis software 
(Wake Forest University, Winston-Salem, NC). Briefly, the Michaelis-Menten 
equation for dopamine uptake can be written by 
 
d[DA]/dt=[DA]p-Vmax/(Km/[DA]+1) 
 
[DA] is the extracellular concentration of dopamine, [DA]p is the change of 
dopamine release per stimulus, Vmax and Km are Michaelis-Menten constant on 
dopamine reuptake by dopamine transporter. Vmax, which is directly propotional 
to DAT concentration, stayed constant throughout the recording session. The Km 
value, which shows the affinity of DAT at half value of Vmax, was set as 200nM 
in the baseline.  Demon Voltammetry software was used to fit the data into the 
Michaelis-Menten equation. The Michaelis-Menten kinetics assume that (1) each 
stimulus pulses release a fixed amount of dopamine from the presynaptic 
terminals; (2) clearing dopamine mechanism is mainly dependent on uptake via 
the DAT; (3) uptake is a saturable process with limited affinity/concentration of 
DAT (Wightman et al., 1988; Yorgason, España, & Jones, 2011). The percentage 
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changes compared to the baseline (% of baseline) were calculated. An 
independent samples t-test was performed to compare the calculated Km and 
[DA]p (% of baseline) of each condition; vehicle vs. CP55,940 in the acute and 
chronic condition.  
Exponential fit modeling provided by Demon Voltammetry software was also 
used for further mathematical modeling for the dopamine release and uptake. In 
this analysis, baseline (pre-stim cursor), peak (peak cursor) and return to 
baseline (post-stim cursor) were defined (Fig 25 (a)). Briefly, Tau and half-life 
were calculated from exponential fit curve determined by peak cursor and post-
stim cursor position using a least square controlled exponential fit algorithm (Fig 
25 (b)). Area Under Curve (AUC) was calculated as the numeric integration of the 
area between the pre-stim and post-stim cursors. Full width at half height 
(FWHH) was obtained by measuring the time between the rise and decay 
portions at the half-maximal amplitude based on pre-stim cursor and post-stim 
cursor. Tau, FWHH, half-life showed strong correlation which changes in Km and 
reliable measures for detecting changes in DA uptake (Yorgason et al., 2011).  
 
Figure 25. Measures of release and reuptake. (a) Positions of Peak (Purple 
dashed line), Pre-stim (Green dashed line), and Post-Stim (Red dashed line) 
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(b)Half-life, Area under Curve, Tau and FWHH(Full width at half height) base on 
the location of Pre-stim, Post-stime and Peak 
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Results 
 
1. Evoked dopamine signal 
 
To examine the effect of CP55,940 on the dopamine overflow, evoked dopamine 
signal was obtained using FSCV in anesthetized animals. Figure 24 shows 
examples of color plots and concentration-time plots of baseline and acute 
CP55,940 injection; the concentration-time plots (Fig 26 (a)) showed the current 
changes at ~+0.6V (white dashed line in Fig 26 (b)) in response to the applied 
electrical stimulation (red bar below the concentration-time plot). The current 
(represented in color) was plotted against the applied voltage (-0.4 to 1.3V) and 
dopamine was detected at its oxidation peak (~+0.6V, green color) during the 
electrical stimulation.  Cyclic voltammogram (inset of the concentration-time plot) 
showed the oxidation peak at ~ +0.6 V and reduction peak at ~ -0.2 V that is 
identical to the chemical signature of dopamine.  
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Figure 26. Concentration versus time plot (upper panel) with 
voltammogram (inset) and representative color plots (lower panel) before 
the treatment (a) after acute injection of CP55,940 (b). (a) Concentration-time 
plots represent the concentration of dopamine over time. Red bar below the plot 
indicate the duration of electrical stimulation. Acute injection of CP55,940 
increased dopamine concentration. Cyclic voltammogram (inset) showed the 
chemical signature of dopamine that is oxidized at ~+0.6V and reduced at ~-0.2V. 
(b) In the color plot, x-axis represents time (s), the y-axis represents applied 
potential to the electrode (V) and current was shown in color (nA, scale on right). 
Dopamine was detected at its peak of oxidation (~ +0.6 V, dashed white line, 
green color).  
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The acute CP55,940 treatment (0.2mg/kg, i.p.injection) significantly increased the 
evoked dopamine concentration (% of baseline) compared to the acute vehicle 
treatment (independent t-test, p<.05, Fig 27, Table 3). The acute CP55,940 
treatment increased the dopamine concentration about 20% compared to the 
baseline (pre-treatment). The chronic CP55,940 treatment did not show a 
significant difference in evoked dopamine concentration (% of baseline) 
compared to the chronic vehicle treatment. However, the concentration changes 
in the chronic CP55,940 treatment was significantly lower than that of the acute 
CP55,940 treatment (independent t-test, p<.05). 
 
Table 3. Percentage changes from baseline in evoked dopamine signal 
following acute or chronic treatment with vehicle or CP55,940 
Group % of baseline (±SEM) 
Acute vehicle 93.87 % (± 6.851) 
Acute CP55,940 119.7 % (± 6.647) 
Chronic vehicle 106.3 % (± 15.28) 
Chronic CP55,940 92.77 % (± 4.721). 
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Figure 27. Percentage changes from baseline in the evoked dopamine 
signal following acute or chronic exposure of vehicle or CP55,940 Acute 
CP55,940 (0.2mg/kg, i.p.) significantly increased evoked dopamine concentration 
compared to acute vehicle injection. Chronic CP55,940 did not show a significant 
change in evoked dopamine concentration compared to both vehicle groups, but 
Chronic CP55,940 was significantly lower than acute CP55,940. Error bar 
represents SEM, independent sample t-test, *p<.05  
 
2. Pre-injection evoked dopamine response   
 
Averaged evoked dopamine concentration before either vehicle or CP55,940 
treatment were compared by one way ANOVA with Bonferroni’s multiple 
comparisons. There were no significant differences across the groups. The mean 
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0.1801), and 0.1013 μM (±0.0337) for the acute group, chronic vehicle group, 
and chronic CP55,940 group, respectively.  
 
3. Michaelis-Menten modeling 
 
1)[DA]p – dopamine release per stimulus  
The modeled [DAp], the amount of the dopamine concentration by each pulse, 
showed a significant increase after acute CP55,940 injection compared to vehicle 
injection and chronic CP55,940 (Fig 28, Table 4). An independent t-test 
confirmed the significant difference between the acute CP55,940 vs. the acute 
vehicle as well as the acute CP55,940 vs. the chronic CP55,940 treatment 
(p<.05). 
 
 
Figure 28. [DA]p of Michalis Menten modleing. A significant increase in [DA]p, 
dopamine release per stimulus pulsewas found in acute CP55,940 treatment 
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when compared to acute vehicle and chronic CP55,940. Error bar represents 
SEM, independent sample t-test, *p<.05  
 
Table 4. The percentage changes (% of baseline) in the [DA]p following 
acute or chronic exposure of vehicle or CP55,940 
Group % of baseline (±SEM) 
Acute vehicle 99.17 % (± 1.688) 
Acute CP55,940 121.0 % (± 5.477) 
Chronic vehicle 101.1 % (± 8.284) 
Chronic CP55,940 94.84 % (± 3.249) 
 
 
2) Km – dopamine reuptkae 
Along with the dopamine release ([DAp]), the amount of dopamine reuptake by 
dopamine transporter was modelled. The Km value in Michaelis Menton kinetic 
represents dopamine transfer function at ½ Vmax, serving as a measure of 
dopamine transporter efficiency (Johnson, Rajan, Miller, & Wightman, 2006). The 
modelled Km value showed that the CP55,940 treatments, both acute and 
chronic treatment, were not significantly different from the vehicle treatments.  
The Km values after the treatments did not significantly differ from the Km value 
in the baseline. 
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4. Exponential Fit Modeling 
 
1) Area Under Curve (AUC) 
 
Acute CP55,940 treatment significantly increased the AUC compared to the 
acute vehicle injection (independent t-test, p<.01) (Fig 29, Table 5). Compared to 
the baseline, acute CP55,940 treatment increased the AUC by about 20% that 
was consistent to the changes in dopamine concentration. The chronic CP55,940 
treatment did not show a significant difference in the AUC (% of baseline) 
compared to the chronic vehicle treatment. However, the AUC of the chronic 
CP55,940 treatment was significantly lower than that of the acute CP55,940 
treatment (independent t-test, p<.01, Fig 29, Table 5). 
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Figure 29. Changes in AUC (% of baseline) after acute and chronic 
treatment. A significant increase in AUC (Area Under Curve) was found in acute 
CP55,940 treatment when compared to acute vehicle and chronic CP55,940 
Error bar represents SEM, independent sample t-test, **p<.01  
 
 
Table 5. The percentage changes (% of baseline) in the AUC following 
acute or chronic exposure of vehicle or CP55,940 
Group % of baseline (±SEM) 
Acute vehicle 93.81 % (± 3.379) 
Acute CP55,940 118.5 % (± 2.757) 
Chronic vehicle 102.0 % (± 15.43) 
Chronic CP55,940 93.43 % ± (3.302) 
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2) Tau  
 
Tau, decay time constant, slightly increased after acute CP55,940 treatment 
compared to the acute vehicle injection, however, the difference between two 
groups was not significant; the change in Tau values relative to the baseline were 
104.9 % (±12.22) for acute vehicle and 111.4% (±11.42) for acute CP55,940 
treatment. Also, there was no significant difference between the chronic vehicle 
versus the chronic CP55,940 groups; 98.78 (±5.454) for the chronic vehicle 
treatment; 97.37% (±4.233) for the chronic CP55,940 treatment. 
 
 
3) Full width at half height (FWHH) 
FWHH, a time between rise and decay portion of the trace at half value of the 
peak, was obtained and compared across the groups in acute and chronic 
treatment. Acute CP55,940 treatment slightly increased the value of FWHH 
slightly, but it was not statistically significant (independent sample t test); 104.1% 
(± 14.01) for acute vehicle treatment and 122.7% (± 6.316) for acute CP55,940 
treatmen. Also, there was no significant difference between the chronic vehicle 
versus the CP55,940 groups; 103.6% (± 2.487) for the chronic vehicle treatment; 
and 96.15% (± 2.071) for the chronic CP55,940 treatment. 
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4) Half-life  
Like a Tau, the half-life (= the time when the peak decay by one half) slightly 
increased after acute CP55,940 treatment compared to vehicle treatment but it 
was not significant. The change of half-life value relative to the baseline was 
103.1% (± 13.85) for the acute vehicle treatment and 111.4% (± 11.42) for the 
acute CP55,940 treatment Also, there was no significant difference between the 
chronic vehicle versus the CP55,940 groups; 98.78% (± 5.454) for the chronic 
vehicle treatment; and 97.37% (± 4.233) for the chronic treatment. 
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Discussion 
 
To the best of my knowledge, this voltammetry study offers the first in vivo 
characterization of dopamine dynamics on the NAc core under acute as well as 
chronic cannabinoid treatment. Using FSCV and kinetic analysis, this study 
measured both release and reuptake elements in the dopamine signal in the NAc 
core, where dopamine transporters are more abundantly expressed than shell 
(Nirenberg et al., 1997). Acute treatment of CP55,940 increased the evoked 
dopamine concentration by 20% relative to baseline, and this effect disappeared 
after the seventh day of injection.  
 
This result suggests that acute cannabinoid exposure increases dopamine 
overflow in the NAc core mainly due to an increase in evoked dopamine release, 
not by inhibition in dopamine reuptake. The increase in evoked dopamine release 
did not last after one week of daily cannabinoid treatment, implying that there are 
mechanisms for developing tolerance.  The kinetic analysis of dopamine overflow 
suggests that  [DA]p, dopamine release per stimulus, and AUC (area under 
curve), were significantly increased in response to acute CP55,940 treatment. 
The degree of increase in AUC corresponds to that of the evoked dopamine 
concentration (both 20%) and those increase rates are supported by the 20% 
increase in [DA]p level.  
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Moreover, neither acute nor chronic treatment of CP55,940 (0.2mg/kg, i.p.) 
altered the measurement of dopamine reuptake; Km, Tau, Full width at half 
height (FWHH), and half-life.  Km value in the Michaelis-Menten equation and 
Tau, FWHH, and half-life value obtained from mathematical modeling are 
measurements of dopamine reuptake levels and showed strict correlations 
between those values (Yorgason et al., 2011). In that those values did not show 
significant difference compared to the baseline, we can propose that cannabinoid 
treatment did not alter dopamine transporter function.  
 
The result suggests that cannabinoids increased dopamine release rather than 
altered dopamine transporter functions. An FSCV study showed that intravenous 
cannabinoid injection increased dopamine transient in NAc in freely moving rats 
(Cheer et al., 2004). Also, this study suggested that cannabinoids may not be 
involved in the reuptake because clearance rates remained unchanged after 
cannabinoid treatment.  Moreover, an in vitro study also supported that 
cannabinoids did not change the reuptake level of dopamine in striatal slices 
(Köfalvi et al., 2005). However, other studies suggested the opposite; 
cannabinoids can alter the reuptake rate by inhibiting dopamine transporter 
function. Price and his colleagues examined dopamine clearance under 
cannabinoids using in vivo and in vitro assay and concluded that cannabinoids 
could inhibit dopamine reuptake (Price et al., 2007). A similar study also 
suggested that that both endogenous and exogenous cannabinoid receptor 
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agonists interacted with the dopamine transporter and inhibited the reuptake 
process (Pandolfo et al., 2011).  Both studies have in common that they 
measured reuptake level in synaptosomes in rodent striatum as well as the 
inhibition of dopamine transporter being independent upon cannabinoid receptor 
function.  
 
The discrepancy in the cannabinoid induced effect on dopamine transporter 
function may come from 1) different brain regions: NAc (this dissertation work 
and Cheer’s work vs. entire (Kofalvi’s work) or dorsal striatum (Pandolfi’s work); 2) 
different techniques for measuring reuptake: in vivo (the dissertation work and 
Cheer’s work) and in vitro for others. Even though Price and his colleagues 
provide in vivo technique (high-speed chronoamperometry) in anesthetized 
animals, the differences between the FSCV and high-speed chronoamperometry 
may create the inconsistent results in terms of time scale of measurement 
(subsecond vs. minute). 
 
One of the potential mechanisms underlying the observed increase in rapid 
dopamine release after acute cannabinoid treatment is increased burst firing 
rates of VTA dopaminergic neurons (Cheer, Marsden, Kendall, & Mason, 2000b; 
Wu & French, 2000). This increased VTA dopaminergic neuronal firing is further 
supported by inhibition of GABA release to VTA neurons under cannabinoid 
exposure (Lecca, Melis, Luchicchi, Ennas, Castelli, Muntoni, et al., 2011a). A 
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previous FSCV study in freely moving animals also reported an increased level of 
dopamine transient which was blocked by CB receptor antagonist (Cheer, 
Marsden, Kendall, & Mason, 2000a). Furthermore, the possible role of 
cannabinoid on facilitating dopamine release in the dopaminergic terminals will 
be another potential underlying mechanism increasing dopamine signals. Recent 
finding suggests that cannabinoid modulates dopamine release by interacting 
with adenosine receptor (Ferré et al., 2010). Moreover, another finding indicates 
that cannabinoids increase dopamine signal by inhibiting dopamine monoamine 
oxidase (Fišar, 2012). Thus, in addition to increasing dopaminergic neuronal 
firing, emerging evidence also shed light on a possible role of cannabinoid in the 
dopaminergic terminals as well. 
 
Moreover, the present results indicate that the cannabinoid-induced changes in 
dopamine overflow develop tolerance after repeated treatments. A recent finding 
using FSCV also suggests that repeated cannabinoid exposure reduced 
dopamine releasing effects (Oleson, Ranganath, Karamsetty, & Cheer, 2014); 
repeated WIN treatment caused tolerance to cannabinoid-induced behavior effect 
well as dopamine releasing effect. In that down-regulation of CB1 receptor is 
thought to be involved in the development of cannabinoid tolerance (González, 
Cebeira, & Fernández-Ruiz, 2005; Martin et al., 2004), repeated treatments in the 
present study may return CB1 receptor signaling back to the baseline, 
presumably by reducing CB1 receptor function.   
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Overall, by using FSCV and kinetic analysis to separate release and uptake 
components of the dopamine overflow, this dissertation work provides 
characterization of in vivo dopamine dynamic under cannabinoid exposure. Our 
results show that although CB1 receptor activation increases NAc dopamine 
concentration and tolerance develops to this effect with chronic treatment. Thus, 
altered dopamine signaling in the reward pathway by acute and chronic 
cannabinoid exposure may contribute to differential changes in motivational state 
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General Discussion 
As a part of the mesolimbic pathway, NAc modulates emotional and motivational 
states. The manipulation of CB1 signaling within the NAc has been found to 
cause robust changes in emotional and motivational states related to drug 
addiction and other psychopathological conditions (Winters et al., 2012). The 
research conducted for this dissertation examined the neuronal adaptation in the 
NAc core under cannabinoid exposure. The study examined two main changes in 
the NAc core: neuronal activity and dopamine dynamics under the acute and 
repeated activation of CB receptors. The main finding suggested that 
cannabinoids reduced neuronal signaling and disrupted functional 
communication, which lasted after repeated treatment. Moreover, the 
cannabinoids increased the evoked dopamine release without altering the 
dopamine reuptake, but this effect disappeared after repeated treatment. 
Because CB receptor activation attenuates presynaptic excitatory and inhibitory 
input, the examination of all components of the CB receptor could help in 
understanding the functional output of CB receptor activation. 
 
Based on the presented results, neuroadaptation of NAc neuronal signaling and 
dopamine dynamics can be potentially explained by two separate adaptive 
mechanisms; glutamate projection to the NAc core vs. dopaminergic projection to 
the NAc core. Consistent with the previous studies, the present study confirms 
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cannabinoid reduced NAc neuronal activity presumably by inhibiting presynaptic 
glutamate release (Mato et al., 2005; Robbe et al., 2001). The inhibited glutamate 
release is possibly involved in the reduced neuronal activity found in the present 
study. Moreover, increased evoked dopamine release in this present study also 
can be explained by CB receptor induced disinhibition of VTA dopaminergic 
neurons (Oleson et al., 2012). Moreover, increased excitability and burst firing of 
dopaminergic neurons promote the endocannabionid release which further 
facilitate CB receptor mediated disinhibition of VTA (Fitzgerald, Shobin, & Pickel, 
2012). Excitatory glutamatergic input from the prefrontal cortex and dopaminergic 
input from VTA projects are assumed the underlying mechanisms of the altered 
neuronal signal and dopamine dynamic in the present study. In fact, the 
interaction of these two projections in the NAc is required for behavioral 
adaptation in goal directed behavior (Pennartz et al., 1994; Wang et al., 2012).   
 
The discrepancy in cannabinoid induced tolerance between neuronal signal and 
dopamine dynamic in NAc core implies a regional difference in the development 
of tolerance. Chronic exposure of cannabinoid reduced CB receptor signaling, 
and these changes were closely associated with cannabinoid induced behavioral 
effects (González et al., 2005; Martin et al., 2004). The CB1 down-regulation is 
larger and takes place more rapidly in the cortical area than in the subcortical 
area including basal ganglia and midbrain (Martin et al., 2004)). In fact, a recent 
human study clearly revealed that chronic marijuana smoking showed 
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significantly lowered CB1 receptor density in the midbrain but not in striatum 
(Hirvonen et al., 2012).  This regional difference may provide evidence as to why 
NAc dopamine signaling (Midbrain CB receptor involved) develops tolerance 
whereas NAc neuronal signaling (NAc CB receptor involved) does not.  
 
In addition to the regional difference, various cannabinoid effects show different 
behavioral aspect of tolerance. For example, tolerance for memory impairment 
develops rapidly, but not for feelings of euphoria in humans (D'Souza et al., 
2008). In animal studies, repeated administration of cannabinoids diminish 
cannabinoid effects on responses in locomotion, antinociception, and 
hypothermia (Maldonado, 2002). It is not fully understood how the changes in 
rewarding effects of cannabinoids function. The lower tolerance for feeling high 
might be supported by the present finding of persistently decreased NAc 
neuronal signaling; persistent reduction in NAc core signaling may reduce 
inhibitory NAc input to the VTA, which might play a role in maintaining increased 
VTA neuronal excitability after repeated cannabinoid treatment. Consistently 
enhanced VTA neuronal firing after repeated cannabinoid administrations in 
previous studies (Cheer, Marsden, Kendall, & Mason, 2000a; Wu & French, 
2000) are therefore supported by the present finding showing steady NAc firing 
inhibition under chronic cannabinoid treatment. 
 
Consistently enhanced VTA neuronal firing in previous studies may contradict to 
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the present voltammetry results. If the VTA dopaminergic activity is sustained 
consistently, it can be expected that evoked dopamine release also remains 
unaltered after repeated cannabinoid treatment. However, it is also possible that 
evoked dopamine release can be regulated primarily in the dopaminergic 
terminal rather in the cell body. Applied frequency of stimulation (60Hz) is higher 
than burst rate of dopaminergic neuron (~20Hz) and could dominate the 
cannabinoid-induced effect on increasing dopaminergic neuronal activity.  
This dissertation study chose non-contingent drug exposure (i.p. injection) that 
potentially recruits different neuronal mechanisms than those involved in 
volunteer drug taking. Moreover, neuronal activities measured in freely moving 
animals examined the spontaneous neuronal discharge under cannabinoid 
exposure. However, the dopamine dynamic was measured in anesthetized 
animal for the precise kinetic modeling process, which separates dopamine 
release and reuptake portions.  This study proposed to examine dopamine and 
glutamate interplay in the NAc core, but further consideration is required to 
interpret because neuronal activity and dopamine dynamics measured in different 
waking states (freely moving condition vs. anesthetized condition).  Moreover, 
even though the dose used in this study is assumed to intrigue rewarding effects 
based on previous studies, lacks behavioral measurements that examine actual 
rewarding properties of cannabinoid was one of the limitations of this study. 
Behavioral measurement that concerns the development of cannabinoid induced 
behavioral tolerance potentially support NAc signal change found in this study. 
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Cannabinoids emerge as a therapeutic target for treatment of depression (Segev, 
Rubin, Abush, Richter-Levin, & Akirav, 2014), drug addiction (López Moreno, 
González Cuevas, Moreno, & Navarro, 2008) , and movement disorder (van der 
Stelt & Di Marzo, 2003). Veiled side effects or tolerance development with 
repeated use limits the cannabinoid for therapeutic use. This dissertation work 
provides particularly the potential effects of cannabinoids on NAc core, a key 
component of the rewarding pathway. As our results indicate, cannabinoids 
inhibited NAc core neuronal activity during initial and prolonged treatment, which 
could provide evidence of changes in motivational states that, in turn, could play 
a role in changing reward-related behaviors. Cannabinoid induced alterations 
presented in this study can further explain the underlying mechanism of NAc 
mediated behavioral adaptation in the decision making process. 
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